OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double‐blind, randomized, placebo‐controlled phases of the PREEMPT clinical …
DW Dodick, CC Turkel, RE DeGryse… - … : The Journal of …, 2010 - Wiley Online Library
(Headache 2010; 50: 921‐936) Objective.—To assess the efficacy, safety, and tolerability of
onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic migraine …
onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic migraine …
OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56‐week PREEMPT clinical program
SK Aurora, P Winner, MC Freeman… - … : The Journal of …, 2011 - Wiley Online Library
Objective.—To evaluate safety and efficacy of onabotulinumtoxinA (BOTOX®) as headache
prophylaxis in adults with chronic migraine. Background.—Chronic migraine is a prevalent …
prophylaxis in adults with chronic migraine. Background.—Chronic migraine is a prevalent …
Development of onabotulinumtoxinA for chronic migraine
SM Whitcup, CC Turkel, RE DeGryse… - Annals of the New York …, 2014 - Wiley Online Library
Discovery of the neuromuscular effects of botulinum toxin began in the early 19th century
and has continued to evolve. Currently, onabotulinumtoxinA is approved by the US Food …
and has continued to evolve. Currently, onabotulinumtoxinA is approved by the US Food …
OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at …
SD Silberstein, AM Blumenfeld, RK Cady… - Journal of the …, 2013 - Elsevier
Acute headache medication overuse (MO) is common in patients with chronic migraine
(CM). We evaluated safety and efficacy of onabotulinumtoxinA as preventive treatment of …
(CM). We evaluated safety and efficacy of onabotulinumtoxinA as preventive treatment of …
Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial
SD Silberstein, SR Stark, SM Lucas, SN Christie… - Mayo Clinic …, 2005 - Elsevier
OBJECTIVES To identify a treatment-responsive population for botulinum toxin type A
(BoNTA) and to evaluate the safety and efficacy of 3 different doses of BoNTA as …
(BoNTA) and to evaluate the safety and efficacy of 3 different doses of BoNTA as …
[HTML][HTML] Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine
R Rendas-Baum, M Yang, SF Varon… - Health and quality of life …, 2014 - Springer
Abstract Background The Headache Impact Test (HIT)-6 was developed and has been
validated in patients with various types of headache. The objective of this study was to report …
validated in patients with various types of headache. The objective of this study was to report …
Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
SD Silberstein, DW Dodick, SK Aurora… - Journal of Neurology …, 2015 - jnnp.bmj.com
Objective The approved use of onabotulinumtoxinA for prophylaxis of headaches in patients
with chronic migraine (CM) involves treatment every 12 weeks. It is currently unknown …
with chronic migraine (CM) involves treatment every 12 weeks. It is currently unknown …
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical …
Background Chronic migraine (CM) is associated with high impact and reduced health-
related quality of life (HRQoL). Methods Patients with CM from PREEMPT (Phase 3 …
related quality of life (HRQoL). Methods Patients with CM from PREEMPT (Phase 3 …
[HTML][HTML] Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example
DW Dodick, CC Turkel, RE DeGryse, HC Diener… - The Journal of …, 2015 - Elsevier
In addition to headache, persons with chronic migraine (CM) experience multiple symptoms,
both ictal and interictal, that may contribute to their suffering. Translating clinical trial results …
both ictal and interictal, that may contribute to their suffering. Translating clinical trial results …
Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: analysis of PREEMPT data
DW Dodick, SD Silberstein, RB Lipton… - …, 2019 - journals.sagepub.com
Background The Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT)
trials demonstrated efficacy/tolerability of onabotulinumtoxinA for headache prevention in …
trials demonstrated efficacy/tolerability of onabotulinumtoxinA for headache prevention in …